Statistics for Comparable safety and non‑inferior immunogenicity of the SARS‑CoV‑2 mRNA vaccine candidate PTX‑COVID19‑B and BNT162b2 in a phase 2 randomized, observer‑blinded study
Total visits
| views | |
|---|---|
| Comparable safety and non‑inferior immunogenicity of the SARS‑CoV‑2 mRNA vaccine candidate PTX‑COVID19‑B and BNT162b2 in a phase 2 randomized, observer‑blinded study | 11 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 11 |
File Visits
| views | |
|---|---|
| Reiter_Comparable_2024.pdf | 2 |
Top country views
| views | |
|---|---|
| South Africa | 10 |
| Norway | 1 |
Top city views
| views | |
|---|---|
| Johannesburg | 10 |